Skip to main content

People in the News: New Appointments at Castle Biosciences, Akoya Biosciences, Syapse, More

Castle Biosciences: Toby Juvenal, Kristen Oelschlager, Bob Cook, Matthew Goldberg

Castle Biosciences has promoted Toby Juvenal as chief commercial officer, Kristen Oelschlager as chief operations officer, Bob Cook as senior vice president of research and development, and Matthew Goldberg as a medical director.

Juvenal has served as the company's senior VP of sales since January 2018, and previously served as VP of sales and marketing since joining Castle Bio in October 2008. He has more than 28 years of sales, sales management, and managed care experience in the pharmaceutical, biotechnology, and diagnostics industries.

Oelschlager has served as the company's senior VP of clinical operations since January 2018, and previously served as VP of clinical operations from 2013 to 2018. She joined the company as executive director of operations in October 2008, and has more than 15 years of experience in clinical nursing, clinical operations services, and clinical research.

Cook has served as Castle Bio's VP of research and development since July 2019, previously serving as VP of medical affairs and research and development from April 2018 to July 2019, executive director of research and development from June 2015 to April 2018, and manager of scientific relations from February 2011 to June 2015.

Goldberg perviously served as an assistant professor in dermatology and pathology at the Icahn School of Medicine at Mount Sinai in New York, and will retain his affiliation as an assistant clinical professor of dermatology. Before joining the Mount Sinai dermatology faculty, Goldberg directed dermatopathology education for the MedStar Georgetown/Washington Hospital Center Dermatology Residency Program.


Akoya Biosciences: Niro Ramachandran, Gavin Gordon

Akoya Biosciences has appointed Niro Ramachandran as its chief business officer and Gavin Gordon as VP of clinical market development.

Ramachandran previously served as VP of NanoString's spatial biology business unit. Prior to NanoString, he held the role of R&D manager at Life Technologies (now part of Thermo Fisher Scientific). In addition, he cofounded and served as chief technology officer of Auguron.

Prior to Akoya, Gordon held senior level positions at Fluidigm and Thermo Fisher Scientific. He has also served as assistant professor at Harvard Medical School and as a faculty member of Brigham and Women's Hospital and Dana-Farber/Harvard Cancer Center.


Syapse: David Pomerantz

Syapse has appointed David Pomerantz as chief commercial officer. Pomerantz joins Syapse from Kantar Health, where he worked for more than a decade including as leader of the RWE Client Partner sales team for the Americas and Europe. He was also responsible for Kantar’s acquisition of Brazilian oncology-focused healthcare consulting firm Evidencias.


For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.